Genetic variability in the RAGE gene: Possible implications for nutrigenetics, nutrigenomics, and understanding the susceptibility to diabetic complications

Molecular Nutrition and Food Research

Volumn 49, Issue 7, 2005, Pages 700-709

  Kaňková, Kateřina ^a   Šebeková, Katarína ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b SLOVAK MEDICAL UNIVERSITY   (Slovakia)

Author keywords

Advanced glycation end product; Diabetes; Glycoxidation; Nutrigenetics; RAGE; Review

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

BLOOD; CONFERENCE PAPER; DIABETES MELLITUS; DIET; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GLYCOSYLATION; HUMAN; METABOLISM; NUTRITION; OXIDATION REDUCTION REACTION;

DIABETES COMPLICATIONS; DIET; GENETIC PREDISPOSITION TO DISEASE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NUTRITION PHYSIOLOGY; OXIDATION-REDUCTION; RECEPTORS, IMMUNOLOGIC; VARIATION (GENETICS);

EID: 22444443197     PISSN: 16134125     EISSN: None     Source Type: Journal    
DOI: 10.1002/mnfr.200500007     Document Type: Conference Paper

References (96)

1. Kaput, J., Diet-disease gene interactions. Nutrition 2004, 20, 26-31.
2. Vlassara, H., Palace, M. R., Glycoxidation: the menace of diabetes and aging. Mt. Sinai J. Med. 2003, 70, 232-241.
3. Baynes, J. W., Thorpe, S. R., Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 2000, 28, 1708-1716.
4. Munch, G., Deuther-Conrad, W., Gasic-Milenkovic, J., Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease - a target for neuroprotective treatment strategies? J. Neural. Transm. Suppl. 2002, 62, 303-307.
5. DeGroot, J., The AGE of the matrix: chemistry, consequence and cure. Curr. Opin. Pharmacol. 2004, 4, 301-305.
6. Finot, P., Historical Perspective of the Maillard Reaction in Food Science. Ann. N.Y. Acad. Sci. 2005, 1043, in press.
7. ε-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 1991, 30, 1205-1210.
8. Takedo, A., Yasuda, T., Miyata, T., Mizuno, K., et al., Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci. Lett. 1996, 221, 17-20.
9. Odani, H., Shinzato, T., Matsumoto, Y., Usami, J., Maeda, K., Increase in three α,β-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem. Biophys. Res. Commun. 1999, 256, 89-93.
10. Ando, K., Beppu, M., Kikugawa, K., Nagai, R., Horiuchi, S., Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. Biochem. Biophys. Res. Commun. 1999, 258, 123-127.
11. DeGroot, J., Verzijl, N., Bank, R. A., Lafeber, F. P., et al., Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation. Arthritis Rheum. 1999, 42, 1003-1009.
12. Verzijl, N., DeGroot, J., Oldehinkel, E., Bank, R. A., et al., Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem. J. 2000, 350, 381-387.
13. DeGroot, J., Verzijl, N., Jacobs, K. M., Budde, M., et al., Accumulation of advanced glycation endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage 2001, 9, 720-726.
14. Sell, D. R., Carlson, E. C., Monnier, V. M., Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetologia 1993, 36, 936-941.
15. Chellan, P., Nagaraj, R. H., Protein cross-linking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. Arch. Biochem. Biophys. 1999, 368, 98-104.
16. Pokupec, R., Kalauz, M., Turk, N., Turk, Z., Advanced glycation endproducts in human diabetic and non-diabetic cataractous lenses. Graefes Arch. Clin. Exp. Ophthalmol. 2003, 241, 378-384.
17. Sebekova, K., Podracka, L., Blazicek, P., Syrova, D., et al., Plasma levels of advanced glycation end products in children with renal disease. Pediatr. Nephrol. 2001, 16, 1105-1112.
18. Odani, H., Shinzato, T., Matsumoto, Y., Takai, I., et al., First evidence for accumulation of protein-bound and protein-free pyrraline in human uremic plasma by mass spectrometry. Biochem. Biophys. Res. Commun. 1996, 224, 237-241.
19. Friedlander, M. A., Witko-Sarsat, V., Nguyen, A. T., Wu, Y. C., et al., The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin. Nephrol. 1996, 45, 379-382.
20. Kalousova, M., Sulkova, S., Fialova, L., Soukupova, J., et al., Glycoxidation and inflammation in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2003, 18, 2577-2581.
21. Sakata, N., Meng, J., Jimi, S., Takebayashi, S., Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis 1995, 116, 63-75.
22. Stitt, A. W., He, C., Friedman, S., Scher, L., et al., Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol. Med. 1997, 3, 617-627.
23. Horie, K., Miyata, T., Maeda, K., Miyata, S., et al., Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J. Clin. Invest. 1997, 100, 2995-3004.
24. Thornalley, P. J., Battah, S., Ahmed, N., Karachalias, N., et al., Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 2003, 375, 581-592.
25. Thornalley, P. J., Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Trans. 2003, 31, 1343-1348.
26. Wu, X., Monnier, V. M., Enzymatic deglycation of proteins. Arch. Biochem. Biophys. 2003, 419, 16-24.
27. Delpierre, G., Rider, M. H., Collard, F., Stroobant, V., et al., Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase. Diabetes 2000, 49, 1627-1634.
28. Szwergold, B. S., Howell, S., Beisswenger, P. J., Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo. Diabetes 2001, 50, 2139-2147.
29. Bulteau, A. L., Verbeke, P., Petropoulos, I., Chaffotte, A. F., Friguet, B., Proteasome inhibition in glyoxal-treated fibroblasts and resistance of glycated glucose-6-phosphate dehydrogenase to 20 S proteasome degradation in vitro. J. Biol. Chem. 2001, 276, 45662-45668.
30. Thornalley, P. J., Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem. Soc. Trans. 2003, 31, 1372-1377.
31. Baynes, J. W., The Maillard hypothesis on aging: time to focus on DNA. Ann. N.Y. Acad. Sci. 2002, 959, 360-367.
32. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813-820.
33. Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., et al., Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001, 50, 2792-2808.
34. Evans, J. L., Goldfine, I. D., Maddux, B. A., Grodsky, G. M., Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev. 2002, 23, 599-622.
35. Pennathur, S., Heinecke, J. W., Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front. Biosci. 2004, 9, 565-574.
36. Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., et al., Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267, 14998-15004.
37. Schmidt, A. M., Vianna, M., Gerlach, M., Brett, J., et al., Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992, 267, 14987-14997.
38. Vlassara, H., Li, Y. M., Imani, F., Wojciechowicz, D., et al., Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol. Med. 1995, 1, 634-646.
39. Li, Y. M., Mitsuhashi, T., Wojciechowicz, D., Shimizu, N., et al., Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. USA 1996, 93, 11047-11052.
40. Araki, N., Higashi, T., Mori, T., Shibayama, R., et al., Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur. J. Biochem. 1995, 230, 408-415.
41. Horiuchi, S., Sakamoto, Y., Sakai, M., Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003, 25, 283-292.
42. Gugliucci, A., Bendayan, M., Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996, 39, 149-160.
43. Odetti, P., Cosso, L., Pronzato, M. A., Dapino, D., Gurreri, G., Plasma advanced glycosylation end-products in maintenance haemodialysis patients. Nephrol. Dial. Transplant. 1995, 10, 2110-2113.
44. Friedlander, M. A., Wu, Y. C., Schulak, J. A., Monnier, V. M., Hricik, D. E., Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am. J. Kidney Dis. 1995, 25, 445-451.
45. Miyata, T., Ueda, Y., Yoshida, A., Sugiyama, S., et al., Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int. 1997, 51, 880-887.
46. Miyata, T., Ueda, Y., Shinzato, T., Iida, Y., et al., Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J. Am. Soc. Nephrol. 1996, 7, 1198-1206.
47. Miyata, T., Fu, M. X., Kurokawa, K., van Ypersele de Strihou, C., et al., Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int. 1998, 54, 1290-1295.
48. Miyata, T., van Ypersele de Strihou, C., Kurokawa, K., Baynes, J. W., Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 1999, 55, 389-399.
49. Kalousova, M., Zima, T., Tesar, V., Stipek, S., Sulkova, S., Advanced glycation end products in clinical nephrology. Kidney Blood Press. Res. 2004, 27, 18-28.
50. Hansen, B., Svistounov, D., Olsen, R., Nagai, R., et al., Advanced glycation end products impair the scavenger function of rat hepatic sinusoidal endothelial cells. Diabetologia 2002, 45, 1379-1388.
51. Sebekova, K., Kupcova, V., Schinzel, R., Heidland, A., Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. J. Hepatol. 2002, 36, 66-71.
52. Ahmed, N., Thornalley, P. J., Luthen, R., Haussinger, D., et al., Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J. Hepatol. 2004, 41, 913-919.
53. Leslie, R. D., Beyan, H., Sawtell, P., Boehm, B. O., et al., Level of an advanced glycated end product is genetically determined: a study of normal twins. Diabetes 2003, 52, 2441-2444.
54. Kankova, K., Role of genetic variability in systems of receptor-mediated and enzymatic defence against glycation in the long-term consequences of diabetes mellitus. Biochem. Soc. Trans. 2003, 31, 1364-1366.
55. Schmidt, A. M., Vianna, M., Gerlach, M., Brett, J., et al., Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992, 267, 14987-14997.
56. Yan, S. D., Chen, X., Fu, J., Chen, M., et al., RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382, 685-691.
57. Hofmann, M. A., Drury, S., Fu, C., Qu, W., et al., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97, 889-901.
58. Hori, O., Brett, J., Slattery, T., Cao, R., et al., The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270, 25752-25761.
59. Hudson, B. I., Stickland, M. H., Futers, T. S., Grant, P. J., Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001, 50, 1505-1511.
60. Pettersson-Fernholm, K., Forsblom, C., Hudson, B. I., Perola, M., et al., The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003, 52, 891-894.
61. Falcone, C., Campo, I., Emanuele, E., Buzzi, M. P., et al., Relationship between the -374T/A RAGE gene polymorphism and angiographic coronary artery disease. Int. J. Mol. Med. 2004, 14, 1061-1064.
62. Falcone, C., Campo, I., Emanuele, E., Buzzi, M. P., et al., -374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin. Chim. Acta 2005, 354, 111-116.
63. Matsunaga-Irie, S., Maruyama, T., Yamamoto, Y., Motohashi, Y., et al., Relation Between Development of Nephropathy and the p22phox C242T and Receptor for Advanced Glycation End Product G1704T Gene Polymorphisms in Type 2 Diabetic Patients. Diabetes Care 2004, 27, 303-307.
64. Kankova, K., Zahejsky, J., Marova, I., Muzik, J., et al., Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. J. Diabetes Complications 2001, 15, 185-192.
65. Kankova, K., Beranek, M., Hajek, D., Vlkova, E., Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the rage gene are not associated with diabetic retinopathy in NIDDM: pilot study. Retina 2002, 22, 119-121.
66. Kankova, K., Stejskalova, A., Hertlova, M., Znojil, V., Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. Nephrol. Dial. Transpl. 2005, 20, 1093-1102.
67. Koschinsky, T., He, C. J., Mitsuhashi, T., Bucala, R., et al., Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. USA 1997, 94, 6474-6479.
68. Goldberg, T., Cai, W., Peppa, M., Dardaine, V., et al., Advanced glycoxidation end products in commonly consumed foods. J. Am. Diet. Assoc. 2004, 104, 1287-1291.
69. Cai, W., Gao, Q. D., Zhu, L., Peppa, M., et al., Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol. Med. 2002, 8, 337-346.
70. Cai, W., He, J. C., Zhu, L., Peppa, M., et al., High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004, 110, 285-291.
71. Zheng, F., He, C., Cai, W., Hattori, M., et al., Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab. Res. Rev. 2002, 18, 224-237.
72. Lin, R. Y., Reis, E. D., Dore, A. T., Lu, M., et al., Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002, 163, 303-311.
73. Lin, R. Y., Choudhury, R. P., Cai, W., Lu, M., et al., Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003, 168, 213-220.
74. Vlassara, H., Cai, W., Crandall, J., Goldberg, T., et al., Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. USA 2002, 99, 15596-15601.
75. Faist, V., Erbersdobler, H. F., Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann. Nutr. Metab. 2001, 45, 1-12.
76. Faist, V., Wenzel, E., Randel, G., Loewer, C., et al., In vitro and in vivo studies on the metabolic transit of N-carboxymethyllysine. Czech. J. Food Sci. 2000, 18, 116-119.
77. Peppa, M., Brem, H., Ehrlich, P., Zhang, J. G., et al., Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003, 52, 2805-2813.
78. Uribarri, J., Peppa, M., Cai, W., Goldberg, T., et al., Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am. J. Kidney Dis. 2003, 42, 532-538.
79. Wittmann, I., Wagner, Z., Mazak, I., Schinzel, R., et al., Foods rich in advanced glycation end products (AGEs) induce microalbuminuria in healthy persons. Nephrol. Dial. Transplant. 2001, 16, A106.
80. Henle, T., Schweger, V., Ritz, E., Preliminary studies on renal handling of food-derived AGEs. In: International Congress on Uremic Toxicity, Vienna, Austria 1999.
81. Sebekova, K., Hofmann, T., Erbersdobler, H., Boor, P., et al., Effects of AGE-rich versus AGE-poor diet in healthy rats and those with chronic renal insufficiency. In: COST 919 Action: 8th Workshop on melanoids in food and health, Bled, Slovenia 2003.
82. Foerster, A., Kuehne, Y., Henle, T., Studies on absorption and elimination of dietary AGEs. In: 8th International symposium on the Maillard reaction, Charleston, South Carolina, USA 2004.
83. ε- carboxyethyllysine (CEL). Nahrung 2001, 45, 182-188.
84. Sebekova, K., Somoza, V., Hofmann, T., Boor, P., et al., Metabolic effects of alimentary Maillard reaction products in healthy and subtotally nephrectomized rats. In: 8th International symposium on the Maillard reaction, Charleston, South Carolina, USA 2004.
85. Uribarri, J., Peppa, M., Cai, W., Goldberg, T., et al., Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am. Soc. Nephrol. 2003, 14, 728-731.
86. Hofmann, S. M., Dong, H. J., Li, Z., Cai, W., et al., Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002, 51, 2082-2089.
87. Peppa, M., He, C., Hattori, M., McEvoy, R., et al., Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes 2003, 52, 1441-1448.
88. Peppa, M., Uribarri, J., Cai, W., Lu, M., Vlassara, H., Glycoxidation and inflammation in renal failure patients. Am. J. Kidney Dis. 2004, 43, 690-695.
89. Chuyen, N., Arai, H., Nakanishi, T., Are food AGEs toxic in biological systems? In: 8th International symposium on the Maillard reaction, Charleston, South Carolina, USA 2004.
90. Sebekova, K., Krajcoviova-Kudlackova, M., Schinzel, R., Faist, V., et al., Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur. J. Nutr. 2001, 40, 275-281.
91. Ordovas, J. M., Mooser, V., Nutrigenomics and nutrigenetics. Curr. Opin. Lipidol. 2004, 15, 101-108.
92. Vincent, S., Planells, R., Defoort, C., Bernard, M. C., et al., Genetic polymorphisms and lipoprotein responses to diets. Proc. Nutr. Soc. 2002, 61, 427-434.
93. Tiret, L., Gene-environment interaction: a central concept in multifactorial diseases. Proc. Nutr Soc. 2002, 61, 457-463.
94. Talmud, P. J., How to identify gene-environment interactions in a multifactorial disease: CHD as an example. Proc. Nutr. Soc. 2004, 63, 5-10.
95. Zill, H., Bek, S., Hofmann, T., Huber, J., et al., RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem. Biophys. Res. Commun. 2003, 300, 311-315.
96. Kankova, K., Marova, I., Zahejsky, J., Muzik, J., et al., Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism 2001, 50, 1152-1160.